EPS for GlaxoSmithKline plc (GSK) Expected At $0.72

April 24, 2018 - By Clifton Ray

GlaxoSmithKline plc (NYSE:GSK) Logo

Analysts expect GlaxoSmithKline plc (NYSE:GSK) to report $0.72 EPS on April, 25.They anticipate $0.10 EPS change or 16.13 % from last quarter’s $0.62 EPS. GSK’s profit would be $1.77 billion giving it 14.11 P/E if the $0.72 EPS is correct. After having $0.72 EPS previously, GlaxoSmithKline plc’s analysts see 0.00 % EPS growth. The stock increased 0.77% or $0.31 during the last trading session, reaching $40.64. About 256,197 shares traded. GlaxoSmithKline plc (NYSE:GSK) has declined 10.07% since April 24, 2017 and is downtrending. It has underperformed by 21.62% the S&P500.

GlaxoSmithKline plc (NYSE:GSK) Ratings Coverage

Among 6 analysts covering GlaxoSmithKline (NYSE:GSK), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. GlaxoSmithKline had 7 analyst reports since October 26, 2017 according to SRatingsIntel. On Tuesday, January 16 the stock rating was upgraded by Barclays Capital to “Buy”. The stock has “Hold” rating by Cowen & Co on Wednesday, February 14. As per Wednesday, April 4, the company rating was upgraded by BNP Paribas. The firm has “Hold” rating by Cowen & Co given on Monday, December 11. UBS upgraded the shares of GSK in report on Monday, November 27 to “Buy” rating. Bank of America downgraded the shares of GSK in report on Thursday, October 26 to “Hold” rating.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of $100.09 billion. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 46.5 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

GlaxoSmithKline plc (NYSE:GSK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.